ERIS Lifesciences has completed the acquisition of the Nephrology and Dermatology businesses pertaining to the Indian Territory of Biocon Biologics. Powered by Capital Market - Live News

Eris Lifesciences has availed a Term Loan Facility from Citi Bank N.A. amounting to Rs. 280 crore for financing the acquisition of the Nephrology and Dermatology businesses pertaining to the Indian Territory of Biocon Biologics as informed by the Company on 08 November 2023.Powered by Capital Market - Live News

Net profit of ERIS Lifesciences rose 2.60% to Rs 123.43 crore in the quarter ended September 2023 as against Rs 120.30 crore during the previous quarter ended September 2022. Sales rose 9.92% to Rs 500.52 crore in the quarter ended September 2023 as against Rs 455.33 crore during the previous quarter ended September 2022. ParticularsQuarter Ended�Sep. 2023Sep. 2022% Var. Sales500.52455.33 10 OPM %36.1933.26 - PBDT168.33149.55 13 PBT126.24120.93 4 NP123.43120.30 3 Powered by Capital Market - Live News

ERIS Lifesciences will hold a meeting of the Board of Directors of the Company on 8 November 2023.Powered by Capital Market - Live News

ERIS Lifesciences announced that the 17th Annual General Meeting (AGM) of the company will be held on 25 September 2023.Powered by Capital Market - Live News